: Bausch Health stock soars after company says rival application for generic version of its IBS drug can’t be approved until 2029
MarketWatch
MAY 17, 2023
district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan irritable bowel syndrome drug from getting FDA approval until 2029, sending shares higher during regular and after-hours trade. BHC on Wednesday said a U.S.
Let's personalize your content